With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma - ILCN.org (ILCN/WCLC) Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case.

Dr. Anne Tsao made the case for chemo-IO in mesothelioma treatment during a #TTLC25 debate.

Visit ILCN for the full article: bit.ly/4hUMDfv #LCSM

Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks? - ILCN.org (ILCN/WCLC) During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.

Experts weighed the benefits against the risks of combination therapies as frontline treatment for EGFR-mutated NSCLC during #TTLC25. ⚖️

Read more in ILCN: bit.ly/43v09mu #LCSM

Best of TTLC 2025 | IASLC The Best of Targeted Therapies of Lung Cancer (TTLC) 2025 Webinar is designed to bring the data on relevant targets for new therapies to the researchers and hea ...

Missed #TTLC25? Get the highlights & key data in this expert-led webinar covering:
🔹 First-line treatment for EGFR-mutant lung cancer
🔹 Neoadjuvant, perioperative & adjuvant therapies
🔹 Emerging immunotherapy trends

🔗 Save your spot: bit.ly/BestofTTLC25
#LungCancer #Oncology #TargetedTherapies

Together Separately: IASLC Targeted Therapies Recap - Lung Cancer Research Foundation Benjamin Levy, MD; Shirish M Gadgeel, MD; and Isabel Preeshagul, DO, MBS, will will give an overview of the topics discussed during February’s IASLC Targeted Therapies Meeting. Join us live or watch…

Join our March 26 Together Separately livestream for a recap of IASLC's Targeted Therapies of Lung Cancer meeting. Find out the latest in #LungCancer from Dr. Benjamin Levy, Dr. Shirish Gadgeel, and Dr. Isabel Preeshagul. Register now: LCRF.org/together #TTLC25

@benlevylungdoc.bsky.social

Watch: our Board Member & ALKtALK co-host Summer Farmen speaking at @iaslc.bsky.social #TTLC25. Summer shared her moving story, why she got involved in patient advocacy & how she's pushing to re-define the odds for our #lungcancer community.

📺https://youtu.be/Hv_zLbCB23o @sunonmyhip.bsky.social

Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment - ILCN.org (ILCN/WCLC) While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard...

Up for Debate: Should KRAS Inhibitors be promoted to a first-line treatment? Visit ILCN to find out what the experts had to say during #TTLC25: bit.ly/3Ft4i0h

Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents? - ILCN.org (ILCN/WCLC) Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.

Are bispecific antibodies the new anti-PD-(L)1 agents? Two experts debated the science and efficacy at #TTLC25.

Read the recap in ILCN: bit.ly/3DvUCSf

Two weeks after the 2025 IASLC Targeted Therapies in #LungCancer Conference and I'm still processing everything.

Attending scientific conferences like the #TTLC25 as a patient and research advocate is a somewhat surreal experience. I feel both completely ignorant and exceptionally qualified.

Congratulations to our fellow, Sean Dougherty, for his work presented at @iaslc.bsky.social #TTLC25 showing real world outcomes in our cohort treated with tarlatamab at UVA with mentor Rick Hall. Many treated outside DeLLphi-301 eligibility criteria, but ORR still 45%. CRS 73%, ICANS 41%.

Thank you Drs Aggarwal, Bunn, Neal, Reckamp, and @iaslc.bsky.social for the invitation and hosting a fantastic inaugural #TTLC25 meeting in HB! 🍊

Feeling refreshed, energized, and inspired in research, patient care, and advocacy

Thank you, Dr Florez,
for inviting us to record LIVE from #TTLC25 🍊

Fantastic discussions with you and Dr Melina Marmarelis

www.iaslc.org/iaslc-news/l...

It’s always a great pleasure to be part of @iaslc.bsky.social #TTLC25

Great summary of data to date on neo-IO/IO/chemo combos in NSCLC by Dr Jamie Chaft

#TTLC25 @iaslc.bsky.social #lcsm

Dr. Ken Culver, our Director of Research & Clinical Affairs, has been attending IASLC #TTLC25 conference in Huntington Beach, CA.

Have a listen to Ken’s message about how he’s advocating for our lung cancer community.

#research #cancer #lungcancer #stage4 #curecancer @iaslc.bsky.social

Lung Cancer Considered Podcast on the move!

LIVE discussions at #TTLC25 with incredible investigators and patient experts

@iaslc.bsky.social

Excellent talk and framework on the approach to targeted therapies for neuroendocrine tumors by Dr Nathaniel Myall

#TTLC25 #lcsm @iaslc.bsky.social

Important poster presented at #TTLC25 by @jessieross.bsky.social and Alissa Cooper from @mskcancercenter.bsky.social on overlap of DLL3/SEZ6 in high grade neuroendocrine cancers

Great talk by @jia-luo.bsky.social from @danafarber.bsky.social at #TTLC25 talking about NUT carcinoma also highlights recent review www.nature.com/articles/s41...

Dr Mehmet Altan presenting on targeted therapies in clinical trials for thymic malignancies, emphasizing the importance of multicenter collaboration in this cancer

#TTLC25 #lcsm @iaslc.bsky.social

Excellent summary of targeted therapies in clinical trials for mesothelioma, a thoracic malignancy without approved targeted agents by Dr Melina Marmarelis

#TTLC25 @iaslc.bsky.social #lcsm

Great to see that one of the inspirational leaders in our field, Dr Ravi Salgia, is well at @iaslc.bsky.social #TTLC25 and thoughts are with those in the community affected by the recent fires in LA

people.com/doctor-famil... #lcsm #oncsky

Wonderful talk brimming with words of wisdom by Dr Heather Wakelee at the @iaslc.bsky.social #TTLC25 faculty dinner

🌟 Justin Kim (MD-to-be) and Sara Walton (MPH student) presenting on the defining features of NUT carcinoma at #TTLC25

#lcsm #oncsky

🙏🏻 to our collaborators on this effort

Great and well-researched debate by Drs Jessica Lin and Jared Weiss - should TKIs be moved to the adjuvant setting?

#TTLC25 @iaslc.bsky.social #lcsm

Thank you for being part of this journey and this incredible #TTLC25 milestone.

Always nice to meet #LCSM #friends from around the #world 🌎! Thanks @iaslc.bsky.social #TTLC25 for providing platform for collaborations, discussions & just hanging out! @vamsivelcheti.bsky.social @aaronmansfield.bsky.social @elaineshummd.bsky.social and many others! @apoddc @apclc @CUHKMedicine

From psychosocial needs to fertility, sexual health, treatment impact, and timely diagnostics – we’re tackling it all! 💪 #LungCancerAwareness #YoungAdults #MedicalResearch #InnovativeStudies #womeninstem #TTLC25

Get ready for the first-ever #TTLC25 discussion on the demographics of lung cancer, with a special focus on young adults. 💬 Let’s take a trip down #history and see how far we’ve come. 🔙 #LungCancerAwareness #YoungAdults #MedicalMilestones

Excellent presentation by Dr Rebecca Heist on the nuances of bringing KRAS G12C inhibitors into the 1L

#TTLC25 @iaslc.bsky.social #lcsm

So grateful for Summer Farmen’s incredible advocacy and support at @iaslc.bsky.social #TTLC25. Fantastic keynote. Thank you @sunonmyhip.bsky.social 💙👏👏